Story
Nov 19, 2026

Isomorphic Labs’ $5 Billion Bet Must Now Prove AI Can Deliver Medicines

The AI drug-discovery company has raised $5 billion to advance its platform and move candidates toward clinical trials. Its programs have promising preclinical results, but the funding raises expectations for results in patients.

Isomorphic Labs raised $5 billion in a Series C round announced on November 17, 2026, co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and existing backers including Alphabet also participating. The company says the money will accelerate its drug-design platform and move its first therapeutic programs toward clinical trials. CEO Demis Hassabis said the round would support “building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials.”

The raise follows a $2.1 billion Series B in May. It also comes months after Hassabis stepped back as CEO of Google DeepMind to focus on Isomorphic, which spun out of the lab in 2021. In announcing the funding, he framed the company’s ambition as using AI to “radically cut the time & cost to find new medicines.”

The immediate milestone is preclinical, not clinical: Isomorphic reports positive results from internal oncology and immunology programs, while partnered work is also producing encouraging preclinical data. The company’s engine, IsoDDE, combines AI models and agents to design and refine drug candidates. Its existing collaborations include Eli Lilly and Novartis, with potential milestone payments tied to research progress.

For Sequoia, the investment backs a growing portfolio of candidates, not just a technology promise. Partner Konstantine Buhler called Isomorphic’s work “foundational technology for the future of medicine” and praised the team’s translation of AI into drug candidates. Alphabet CEO Sundar Pichai amplified Hassabis’s announcement on X, underscoring the parent company’s support.

The contrast is clear: investors are financing the possibility that AI can transform drug discovery, while the company’s next test is to turn promising laboratory results into treatments that can be evaluated in people.